Page last updated: 2024-08-23

cabergoline and Idiopathic Parkinson Disease

cabergoline has been researched along with Idiopathic Parkinson Disease in 137 studies

Research

Studies (137)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	38 (27.74)	18.2507
2000's	78 (56.93)	29.6817
2010's	19 (13.87)	24.3611
2020's	2 (1.46)	2.80

Authors

Authors	Studies
Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K	1
Akhtar, MF; Akter, R; Al-Harrasi, A; Berrada, M; Bhatia, S; Damiri, F; Ferdous Mitu, J; Kabir, MT; Rahman, MH; Rahman, MS; Saleem, A	1
Ang, YS; Hu, M; Husain, M; Kienast, A; Le Heron, C; Manohar, S; Muhammed, K; Plant, O	1
Ali, F; Fatima, A; Khan, W; Khanam, S; Naqvi, AH; Naz, F; Siddique, YH; Singh, BR; Smita Jyoti, R	1
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ	1
Beuthien-Baumann, B; Grählert, X; Herting, B; Kotzerke, J; Löhle, M; Oehme, L; Perick, M; Reichmann, H; Schwanebeck, U; Storch, A; van den Hoff, J; Wolz, M	1
Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T	1
Canpolat, U; Elibol, B; Ozer, N; Yorgun, H	1
Andersen, M; Dal, J; Jørgensen, JO; Kistorp, C; Laurberg, P; Mægbæk, ML; Nørrelund, H; Steffensen, C	1
Ikeda, S; Ishizaki, T; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H; Yamamoto, M	1
Bianchini, E; Bramanti, P; Cilia, R; Ciurleo, R; de Luise, C; Di Lorenzo, G; Ilardi, M; Italiano, D; Pezzoli, G; Polimeni, G; Rijnbeek, P; Ross, D; Stocchi, F; Sturkenboom, M; Trifirò, G; Vacca, L; Zanettini, R	1
Anheim, M; Benabid, AL; Chabardès, S; Dowsey-Limousin, P; Krack, P; Pollak, P	1
Hiramoto, T; Kikuchi, A; Onodera, J; Onoue, N; Oumi, M; Sato, T	1
Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C	1
Binder, S; Deuschl, G; Volkmann, J	1
Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K	1
Sherlock, M; Steeds, R; Toogood, AA	1
Genís-Batlle, D; Haro-Estarriol, M; Obrador-Lagares, A; Rodríguez-Jerez, F; Sabater-Talaverano, G; Sendra-Salillas, S	1
Kulisevsky, J; Martinez-Corral, M; Pagonabarraga, J	1
Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H	1
Pullan, PT	1
Antonini, A; Gatto, G; Gentile, R; Pezzoli, G; Tesei, S; Zanettini, R	2
Bosco, D; Bosco, F; Consoli, A; Plastino, M; Rotondo, A	1
Kubota, K; Ooba, N; Yamaguchi, T	1
Ikeda, S; Ishizaki, T; Morikawa, K; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H	1
Bötzel, K; Levin, J; Näbauer, M; Neudert, J; Zwermann, L	1
Ceballos-Baumann, AO; Fietzek, UM; Riedl, L	1
Utsumi, H	1
Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P	1
Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H	1
Brunner, H; Friess, E; Hogl, B; Trenkwalder, C; Wetter, TC; Yassouridis, A	1
Gekht, AB	1
Appiah-Kubi, LS; Chaudhuri, KR; Marco, AD	1
Bain, PG; Navan, P	1
Battaglia, A; Canonico, PL; Lombardi, G; Miglio, G; Papini, MG; Varsaldi, F	1
Christensen, J; Dupont, E; ØStergaard, K	1
Clarke, CE; Guttman, M	1
Grauer, MT; Sieb, JP	1
Berardelli, A; De Pandis, MF; Modugno, N; Ruggieri, S; Stocchi, F; Thomas, A; Vacca, L; Valente, M	1
Pastor, P; Tolosa, E	1
Kodama, R; Kondo, T; Miwa, H; Morita, S	1
Högl, B; Rothdach, A; Trenkwalder, C; Wetter, TC	1
Berger, KB; Dodel, RC; DuChane, J; Köhne-Volland, R; Machat, O; Meyer, D; Oertel, WH; Reuther, M; Siebert, U; Smala, AM; Spottke, EA	1
Inzelberg, R; Nisipeanu, P; Schechtman, E	1
Kondo, T; Miwa, H	1
Bernardini, S; Berti, C; Bonuccelli, U; Caneparo, D; Del Dotto, P; Gambaccini, G	1
Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A	1
Harada, H; Hashimoto, H; Kono, I; Nakagawa, M; Yoshida, T; Yoshikawa, K	1
Hotta, M; Kamo, T; Kawakami, M; Nemoto, S; Oshima, J; Shimojo, S; Shiraishi, M; Sugihara, H; Takahashi, Y; Yasaki, S	1
Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H	1
Clarke, CE; Gray, R; Ives, N; Wheatley, K	1
Marras, C	1
MacIver, DH; Townsend, M	1
Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL	1
Curran, MP; Perry, CM	1
Grosset, D; Grosset, K; Macphee, G; Needleman, F	1
Saito, N; Shimizu, M; Shimizu, S; Sugiura, Y; Yamamoto, T	1
Johansen, SS; Karkov, J	1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P	1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Luce, P; Medcalf, P; Odin, P; Stegie, F	1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C	1
Comella, C; Widnell, KL	1
Arthur, K; Foley, SR; Kelly, BD	1
Fortes, J; Marcos-Alberca, P; Pinero, A	1
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G	1
Moritoyo, H; Moritoyo, T; Nagai, M; Nakatsuka, A; Nishikawa, N; Nomoto, M; Nomura, T; Yabe, H	1
Delgrange, E	1
Abe, T; Isobe, C; Kikuchi, T; Murata, T; Sato, C; Terayama, Y	1
Brusa, L; Cervellino, A; Giacomini, P; Grossi, K; Izzi, F; Marciani, MG; Pierantozzi, M; Placidi, F; Romigi, A; Stanzione, P	1
Linazasoro, G; van Blercom, N	1
Fuhrmann, JT; Junghanns, S; Koch, R; Oelwein, C; Reichmann, H; Simonis, G; Storch, A; Strasser, RH	1
Andersohn, F; Garbe, E; Haverkamp, W; Schade, R; Suissa, S	1
Erginöz, E; Kenangil, G; Koldas, L; Ozekmekçi, S; Sahin, T	1
Cağlar, S; Onal, A	1
Deuschl, G; Fox, GC; Gordin, A; Roscher, T; Schremmer, D; Vaitkus, A	1
Senol, MG; Togrol, RE	1
Fuhrmann, JT; Simonis, G; Strasser, RH	1
Antonini, A; Poewe, W	1
Hanada, T; Higaki, Y; Hiroe, K; Inoue, S; Murakami, R; Oda, T; Okada, S; Ota, T; Shimizu, K	1
Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ	1
Dupont, E; Egeblad, H; Poulsen, SH; Rasmussen, VG; Safikhany, G; Østergaard, K	1
Arcoraci, V; Morgante, L; Savica, R; Tari, M; Trifirò, G	1
Dengler, R; Joppich, G; Möbes, J; Schröder, C; Stiebritz, F	1
Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K	1
Brusa, L; Galati, S; Izzi, F; Marciani, MG; Pasqualetti, P; Pierantozzi, M; Placidi, F; Romigi, A; Sperli, F; Stanzione, P	1
Berger, HJ; Horstink, MW; van de Vlasakker, CJ	1
Mark, MH; Sage, JI	1
Lera, G; Obeso, JA; Rodriguez, M; Vaamonde, J	1
Ahlskog, JE; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, MD; Wheeler, K; Wright, KF	1
Ahlskog, JE; Imke, S; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, M; Schoenfelder, J; Wheeler, K; Wright, KF	1
Brewer, MA; Hutton, JT; Morris, JL	1
Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ	1
Inzelberg, R; Korczyn, AD; Nisipeanu, P; Rabey, MJ	1
Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF	1
Rabey, JM	1
Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D	1
Bonuccelli, U; Colzi, A; Del Dotto, P; Dubini, A; Grimaldi, R; Lucetti, C; Pardini, C	1
Adler, CH; Ahlskog, JE; Hiner, BC; Hurtig, HI; Hutton, JT; Koller, WC; Lieberman, A; Morris, JL; Muenter, MD; Pahwa, R; Pfeiffer, RF; Rodnitzky, RL; Stern, MB; Waters, CH	1
Catz, T; Inzelberg, R; Kippervasser, S; Korczyn, AD; Nisipeanu, P; Orlov, E; Rabey, JM; Schechtman, E	1
Caraceni, T; Fetoni, V; Geminiani, G; Genitrini, S; Giovannini, P; Tamma, F	1
Simons, JA	1
Anderson, T; El-Debas, T; Findley, LJ; Marsden, CD; Steiger, MJ	1
Arai, N; Isaji, M; Itoh, F; Kojima, M; Komatsu, Y; Miyagi, M; Taya, F	1
Bracco, F; Chouza, C; Dubini, A; Dupont, E; Gershanik, O; Grimaldi, R; Marsden, CD; Marti Masso, JF; Montastruc, JL; Orlando, N; Rinne, UK	1
Korczyn, AD; Nisipeanu, P	1
Inzelberg, R; Korczyn, AD; Nissipeanu, P; Rabey, JM	1
Bonuccelli, U; Colzi, A; Del Dotto, P; Fariello, R; Musatti, E; Persiani, S; Strolin Benedetti, M	1
Alldredge, BK; Aminoff, MJ; Bainbridge, JL; Dowling, GA; Gottwald, MD	1
LeWitt, PA	2
Fariello, RG	1
Marsden, CD	1
Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marsden, CD; Marti Masso, JF; Montastruc, JL; Rinne, UK	1
Lange, KW	1
Montastruc, JL; Rascol, O; Senard, JM	1
Becke, B; Frank, W; Moritz, R; Pauli, R	1
Lam, YW	1
Bédard, PJ; Di Paolo, T; Falardeau, P; Goulet, M; Grondin, R; Maltais, S; Morissette, M	1
Agapito, C; Bhattacharya, KF; Chaudhuri, KR; Pal, S	1
Clarke, CE; Deane, KH	1
Clarke, CE; Deane, KD	1
Ichikawa, K; Kojima, M	1
Katayama, S	1
Baas, HK; Schueler, P	1
Benecke, R; Dressler, D; Wittstock, M	1
Demedts, M; Dom, R; Frans, E	1
Broutin, F; Fonte, G; Persiani, S; Pianezzola, E; Strolin Benedetti, M	1
Blandini, F; Cavallini, A; Fariello, R; Martignoni, E; Micieli, G; Nappi, G	1
Bhatt, MH; Calne, DB; Fleetham, JA; Keenan, SP	1
Bassi, S; Calloni, E; Camerlingo, M; Canal, N; Franceschi, M; Frattola, L; Giusti, MC; Jori, MC; Mamoli, A; Piolti, R	1
Lera, G; Muruzabal, J; Obeso, JA; Vaamonde, J	1

Reviews

29 review(s) available for cabergoline and Idiopathic Parkinson Disease

Article	Year
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus. Environmental science and pollution research international, 2022, Volume: 29, Issue:31 Topics: Bromocriptine; Cabergoline; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hyperprolactinemia; Parkinson Disease; Restless Legs Syndrome	2022
Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7 Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline	2013
[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients]. Ugeskrift for laeger, 2014, 01-06, Volume: 176, Issue:1 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Parkinson Disease; Ultrasonography	2014
DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17 Suppl 4 Topics: Cabergoline; Dopamine Agonists; Ergolines; Ergot Alkaloids; Humans; Parkinson Disease	2002
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17 Suppl 4 Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone	2002
[Use of dopamine agonists in the treatment of Parkinson's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2002, Volume: 102, Issue:9 Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors	2002
Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:10 Topics: Antiparkinson Agents; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Humans; Movement Disorders; Neuroprotective Agents; Parkinson Disease	2002
Dopamine agonist monotherapy in Parkinson's disease. Lancet (London, England), 2002, Nov-30, Volume: 360, Issue:9347 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2002
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs & aging, 2003, Volume: 20, Issue:11 Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles	2003
Hair loss induced by dopamine agonist: case report and review of the literature. Parkinsonism & related disorders, 2003, Volume: 10, Issue:1 Topics: Aged; Alopecia; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Parkinson Disease	2003
Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs, 2004, Volume: 64, Issue:18 Topics: Antiparkinson Agents; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ergolines; Humans; Parkinson Disease	2004
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5 Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone	2005
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11 Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone	2005
[Treatment of Parkinson disease: therapeutic reserve of the dopaminergic agonist]. Neurologia (Barcelona, Spain), 2006, Volume: 21, Issue:7 Topics: Benzothiazoles; Cabergoline; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Parkinson Disease; Pramipexole	2006
Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2007, Oct-15, Volume: 22, Issue:13 Topics: Antiparkinson Agents; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Combinations; Echocardiography; Ergolines; Ergot Alkaloids; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide; Product Surveillance, Postmarketing	2007
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. The Lancet. Neurology, 2007, Volume: 6, Issue:9 Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide	2007
Second generation of dopamine agonists: pros and cons. Journal of neural transmission. Supplementum, 1995, Volume: 45 Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drugs, Investigational; Ergolines; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles	1995
Newer therapies for Parkinson's disease. Neurologia i neurochirurgia polska, 1996, Volume: 30 Suppl 2 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Parkinson Disease	1996
New pharmacotherapy for Parkinson's disease. The Annals of pharmacotherapy, 1997, Volume: 31, Issue:10 Topics: Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Humans; Indoles; Nitriles; Nitrophenols; Parkinson Disease; Pramipexole; Receptors, Dopamine D2; Thiazoles; Tolcapone	1997
New options for treatment of Parkinson's disease. Bailliere's clinical neurology, 1997, Volume: 6, Issue:1 Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Ergolines; Guidelines as Topic; Humans; Indoles; Nitriles; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone; Treatment Outcome	1997
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs, 1998, Volume: 55 Suppl 1 Topics: Animals; Antiparkinson Agents; Area Under Curve; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2	1998
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs, 1998, Volume: 55 Suppl 1 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic	1998
Clinical pharmacology of dopamine agonists in Parkinson's disease. Drugs & aging, 1998, Volume: 13, Issue:5 Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Ergot Alkaloids; Humans; Indoles; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles	1998
Treatment of Parkinson's disease should begin with a dopamine agonist. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5 Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles	1999
Clinical pharmacology of dopamine agonists. Pharmacotherapy, 2000, Volume: 20, Issue:1 Pt 2 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles	2000
New drugs for the treatment of Parkinson's disease. Pharmacotherapy, 2000, Volume: 20, Issue:1 Pt 2 Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone	2000
Cabergoline for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2001, Issue:1 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2001
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2001, Issue:1 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2001
[Pharmacological effects of cabergoline against parkinsonism]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 117, Issue:6 Topics: Animals; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Haplorhini; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine	2001

Trials

31 trial(s) available for cabergoline and Idiopathic Parkinson Disease

Article	Year
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology, 2013, May-07, Volume: 80, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Corpus Striatum; Dopamine; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Single-Blind Method; Treatment Outcome	2013
Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy. European neurology, 2009, Volume: 61, Issue:3 Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Female; Humans; Linear Models; Male; Monitoring, Ambulatory; Motor Activity; Parkinson Disease; Pilot Projects; Severity of Illness Index; Tremor	2009
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:6 Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome	2009
Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study. Acta medica Okayama, 2012, Volume: 66, Issue:2 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time; Treatment Outcome	2012
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:3 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3	2013
Combination of two different dopamine agonists in the management of Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome	2002
The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:10 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Motor Activity; Nocturnal Myoclonus Syndrome; Parkinson Disease; Polysomnography; Sleep; Treatment Outcome	2003
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs & aging, 2003, Volume: 20, Issue:11 Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles	2003
Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:6 Topics: Aged; Antiparkinson Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Parkinson Disease; Pergolide; Prospective Studies; Treatment Outcome	2004
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS drugs, 2004, Volume: 18, Issue:11 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome	2004
Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta neurologica Scandinavica, 2006, Volume: 113, Issue:1 Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome	2006
Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. Journal of pharmacological sciences, 2006, Volume: 100, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cabergoline; Clarithromycin; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease	2006
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Movement disorders : official journal of the Movement Disorder Society, 2007, Jan-15, Volume: 22, Issue:2 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Hypertrophy, Left Ventricular; Indoles; Male; Middle Aged; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Tricuspid Valve Insufficiency	2007
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. Movement disorders : official journal of the Movement Disorder Society, 2007, Aug-15, Volume: 22, Issue:11 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cabergoline; Catechols; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Dyskinesias; Ergolines; Female; Humans; Male; Medical Records; Middle Aged; Nitriles; Parkinson Disease; Psychiatric Status Rating Scales; Surveys and Questionnaires	2007
Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. Journal of internal medicine, 2008, Volume: 263, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Cabergoline; Cross-Sectional Studies; Denmark; Dopamine Agonists; Electrocardiography; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Logistic Models; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Ultrasonography	2008
Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. Journal of neurology, 2008, Volume: 255, Issue:7 Topics: Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Ergolines; Female; Humans; Male; Middle Aged; Outpatients; Parkinson Disease; Polysomnography; Severity of Illness Index; Sleep; Wakefulness	2008
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Archives of neurology, 1994, Volume: 51, Issue:12 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease	1994
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology, 1993, Volume: 43, Issue:10 Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agents; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine	1993
Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology, 1993, Volume: 43, Issue:3 Pt 1 Topics: Adult; Aged; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease	1993
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clinical neuropharmacology, 1996, Volume: 19, Issue:3 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease	1996
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. Journal of neural transmission. Supplementum, 1995, Volume: 45 Topics: Aged; Amphetamine; Amphetamines; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Methamphetamine; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	1995
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology, 1996, Volume: 46, Issue:4 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Patient Dropouts; Placebos; Treatment Outcome	1996
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology, 1996, Volume: 47, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease	1996
Fluoxetine in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1996, Volume: 11, Issue:5 Topics: Aged; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	1996
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. Journal of neurology, 1996, Volume: 243, Issue:1 Topics: Adult; Aged; Blood Pressure; Cabergoline; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Placebos; Severity of Illness Index; Time Factors	1996
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology, 1997, Volume: 48, Issue:2 Topics: Aged; Antiparkinson Agents; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	1997
Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease. Clinical neuropharmacology, 1994, Volume: 17, Issue:3 Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D2	1994
Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. Clinical neuropharmacology, 1997, Volume: 20, Issue:5 Topics: Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease	1997
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs, 1998, Volume: 55 Suppl 1 Topics: Activities of Daily Living; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors	1998
Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. European neurology, 2001, Volume: 46 Suppl 1 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesias; Ergolines; Female; Humans; Male; Motor Activity; Parkinson Disease; Quality of Life; Sleep; Time	2001
Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. Advances in neurology, 1990, Volume: 53 Topics: Administration, Oral; Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Humans; Male; Neurologic Examination; Parkinson Disease	1990

Other Studies

78 other study(ies) available for cabergoline and Idiopathic Parkinson Disease

Article	Year
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease. Neuroscience research, 2022, Volume: 178 Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger	2022
Dopamine Modulates Option Generation for Behavior. Current biology : CB, 2018, 05-21, Volume: 28, Issue:10 Topics: Adult; Aged; Cabergoline; Decision Making; Dopamine; Dopamine Agents; Dopamine Agonists; Double-Blind Method; Female; Humans; Individuality; Male; Middle Aged; Parkinson Disease; Young Adult	2018
Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson's disease. Toxicology mechanisms and methods, 2018, Volume: 28, Issue:9 Topics: Alginates; alpha-Synuclein; Animals; Animals, Genetically Modified; Behavior, Animal; Cabergoline; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drosophila melanogaster; Longevity; Nanocomposites; Oxidative Stress; Parkinson Disease	2018
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:3 Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture	2013
Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2014, Volume: 14, Issue:2 Topics: Cabergoline; Cohort Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease	2014
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. PloS one, 2014, Volume: 9, Issue:6 Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide	2014
Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:6 Topics: Aged; Antiparkinson Agents; Cabergoline; Cohort Studies; Echocardiography; Ergolines; Female; Guideline Adherence; Heart Valve Diseases; Heart Valves; Humans; Incidence; Italy; Male; Middle Aged; Parkinson Disease; Pergolide; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Risk Factors; Supranuclear Palsy, Progressive	2015
Subthalamic stimulation or subthalamic lesion for Parkinson's disease? A case report. Parkinsonism & related disorders, 2015, Volume: 21, Issue:12 Topics: Adult; Antiparkinson Agents; Cabergoline; Chorea; Combined Modality Therapy; Deep Brain Stimulation; Equipment Failure; Ergolines; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Parkinson Disease; Recurrence; Severity of Illness Index; Subthalamic Nucleus	2015
[Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline]. Rinsho shinkeigaku = Clinical neurology, 2008, Volume: 48, Issue:7 Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Fatal Outcome; Female; Heart Failure; Heart Valve Diseases; Humans; Parkinson Disease	2008
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:2 Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors	2009
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report. European journal of neurology, 2009, Volume: 16, Issue:2 Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole	2009
Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart (British Cardiac Society), 2009, Volume: 95, Issue:7 Topics: Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Parkinson Disease; Pergolide; Tricuspid Valve Insufficiency	2009
[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline]. Archivos de bronconeumologia, 2009, Volume: 45, Issue:2 Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Humans; Hypertension, Pulmonary; Male; Parkinson Disease; Pleural Effusion	2009
Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity. Journal of neurology, 2009, Volume: 256, Issue:5 Topics: Antiparkinson Agents; Arm; Art; Benzothiazoles; Brain; Cabergoline; Creativity; Depressive Disorder; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Motor Skills; Obsessive Behavior; Paintings; Parkinson Disease; Pramipexole	2009
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy. Internal medicine journal, 2009, Volume: 39, Issue:4 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography	2009
Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovascular therapeutics, 2011, Volume: 29, Issue:6 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Italy; Male; Middle Aged; Parkinson Disease; Patient Selection; Pergolide; Prevalence; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Ultrasonography	2011
Clozapine for medication-related pathological gambling in Parkinson disease. Movement disorders : official journal of the Movement Disorder Society, 2010, Sep-15, Volume: 25, Issue:12 Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Clozapine; Ergolines; Female; Gambling; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline; Serotonin Antagonists	2010
The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks? Heart advisor, 2009, Volume: 12, Issue:8 Topics: Antiparkinson Agents; Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Ergolines; Health Knowledge, Attitudes, Practice; Humans; Parkinson Disease; Pergolide	2009
The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug safety, 2011, Apr-01, Volume: 34, Issue:4 Topics: Cabergoline; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Drug Utilization Review; Ergolines; Government Regulation; Heart Valve Diseases; Humans; Insurance Claim Review; Japan; Legislation, Drug; Parkinson Disease; Pergolide; Regression Analysis; Ultrasonography	2011
Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Drug Labeling; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Incidence; Japan; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Risk Factors	2011
Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease. Journal of neurology, 2011, Volume: 258, Issue:11 Topics: Antiparkinson Agents; Cabergoline; Echocardiography, Doppler, Color; Ergolines; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Parkinson Disease	2011
Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline. Parkinsonism & related disorders, 2012, Volume: 18, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Cohort Studies; Cross-Sectional Studies; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Odds Ratio; Parkinson Disease; Retrospective Studies; Risk Assessment	2012
Finasteride attenuates pathological gambling in patients with Parkinson disease. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games	2012
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:5 Topics: Aged; Brain; Cabergoline; Delta Rhythm; Dopamine Agonists; Drug Therapy, Combination; Electroencephalography; Electromyography; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep, REM; Wakefulness	2002
Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2002, Volume: 73, Issue:5 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Tolerance; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Time	2002
Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress. European journal of pharmacology, 2002, Dec-20, Volume: 457, Issue:2-3 Topics: Cabergoline; Cell Death; Cell Survival; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Ergolines; Free Radicals; Haloperidol; Humans; Lipid Peroxidation; Models, Neurological; Necrosis; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Receptors, Dopamine D2; tert-Butylhydroperoxide; Tumor Cells, Cultured	2002
Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6 Topics: Adult; Aged; Antifungal Agents; Antiparkinson Agents; Cabergoline; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Ergolines; Female; Humans; Itraconazole; Male; Neurologic Examination; Onychomycosis; Parkinson Disease; Treatment Outcome	2002
Alopecia induced by dopamine agonists. Neurology, 2002, Dec-24, Volume: 59, Issue:12 Topics: Aged; Alopecia; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Parkinson Disease	2002
[Cabergoline in the treatment of Parkinson's disease]. Neurologia (Barcelona, Spain), 2003, Volume: 18, Issue:4 Topics: Antiparkinson Agents; Brain; Cabergoline; Drug Tolerance; Ergolines; Humans; Parkinson Disease; Randomized Controlled Trials as Topic	2003
[Three patients with Parkinson's disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis]. No to shinkei = Brain and nerve, 2003, Volume: 55, Issue:5 Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cabergoline; Dibenzothiazepines; Ergolines; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate	2003
Cabergoline versus levodopa monotherapy: a decision analysis. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Making; Disease Progression; Ergolines; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; Severity of Illness Index	2003
Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2003, Volume: 24, Issue:3 Topics: Aged; Antiparkinson Agents; Cabergoline; Disorders of Excessive Somnolence; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Ergolines; Female; Humans; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Pilot Projects; Prospective Studies; Psychomotor Performance; Time Factors	2003
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:12 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Ergolines; Female; Locomotion; Macaca fascicularis; Parkinson Disease; Posture	2003
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study. Internal medicine (Tokyo, Japan), 2003, Volume: 42, Issue:11 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cabergoline; Ergolines; Humans; Levodopa; Male; Parkinson Disease; Polysomnography; Sleep Apnea Syndromes	2003
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide	2004
Cabergoline versus levodopa monotherapy. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease	2004
Re: Cabergoline versus levodopa monotherapy: a decision analysis. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Age Factors; Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Surveys and Questionnaires	2004
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease. Heart (British Cardiac Society), 2004, Volume: 90, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Ergolines; Fibrosis; Humans; Male; Middle Aged; Parkinson Disease; Pericarditis, Constrictive; Pleura; Pulmonary Fibrosis	2004
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles	2004
Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease. Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:8 Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Monitoring, Ambulatory; Motor Activity; Parkinson Disease	2004
A fatal overdose of the ergot derivative cabergoline. Forensic science international, 2004, Nov-10, Volume: 146, Issue:1 Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, Ion Exchange; Drug Overdose; Ergolines; Female; Gas Chromatography-Mass Spectrometry; Humans; Liver; Molecular Structure; Parkinson Disease; Spectrometry, Mass, Electrospray Ionization	2004
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12 Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide	2004
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Retrospective Studies	2005
Psychiatric sequelae of Parkinson disease: a case report. European psychiatry : the journal of the Association of European Psychiatrists, 2006, Volume: 21, Issue:3 Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses	2006
Cabergoline-related severe restrictive mitral regurgitation. The New England journal of medicine, 2005, Nov-03, Volume: 353, Issue:18 Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Mitral Valve; Mitral Valve Insufficiency; Parkinson Disease; Ultrasonography	2005
Cabergoline and mitral regurgitation. The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4 Topics: Aged; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Mitral Valve Insufficiency; Parkinson Disease	2006
Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. European journal of neurology, 2006, Volume: 13, Issue:4 Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, High Pressure Liquid; Ergolines; Female; Free Radical Scavengers; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Peroxynitrous Acid; Tyrosine	2006
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. Journal of neural transmission (Vienna, Austria : 1996), 2006, Volume: 113, Issue:12 Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Wakefulness	2006
Dopamine agonists and the risk of cardiac-valve regurgitation. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Case-Control Studies; Cohort Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Logistic Models; Male; Middle Aged; Parkinson Disease; Pergolide; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists	2007
Valvular heart disease and the use of dopamine agonists for Parkinson's disease. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Aged; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Parkinson Disease; Pergolide; Regression Analysis; Risk; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Ultrasonography	2007
Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clinical neurology and neurosurgery, 2007, Volume: 109, Issue:4 Topics: Aged; Antiparkinson Agents; Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Tricuspid Valve Insufficiency	2007
Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations. Chemical & pharmaceutical bulletin, 2007, Volume: 55, Issue:4 Topics: Cabergoline; Dopamine Agents; Ergolines; Humans; Hydrogen-Ion Concentration; Indoles; Parkinson Disease; Pharmaceutical Preparations; Reproducibility of Results; Sensitivity and Specificity	2007
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Parkinson Disease; Patient Selection; Pergolide; Pramipexole; Research Design; Sex Factors	2007
[Mitral valve replacement for cabergoline-related severe mitral regurgitation]. Kyobu geka. The Japanese journal of thoracic surgery, 2007, Volume: 60, Issue:11 Topics: Aged, 80 and over; Antiparkinson Agents; Bioprosthesis; Cabergoline; Chordae Tendineae; Echocardiography; Ergolines; Heart Valve Prosthesis Implantation; Humans; Male; Mitral Valve; Mitral Valve Insufficiency; Parkinson Disease	2007
[Association between amytrophic lateral sclerosis and Parkinson's disease]. Medicina clinica, 2007, Oct-06, Volume: 129, Issue:12 Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed	2007
Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent. Journal of the American Geriatrics Society, 2008, Volume: 56, Issue:2 Topics: Aged; Antiparkinson Agents; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Male; Parkinson Disease; Pergolide; Treatment Outcome	2008
Emotional speech in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-30, Volume: 23, Issue:6 Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Cabergoline; Emotions; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Phonation; Speech	2008
The frequency of cardiac valvular regurgitation in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, May-15, Volume: 23, Issue:7 Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence	2008
Cabergoline in Parkinson's disease. Neurology, 1995, Volume: 45, Issue:6 Topics: Cabergoline; Dopamine Agonists; Ergolines; Humans; Parkinson Disease	1995
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Annals of neurology, 1995, Volume: 37, Issue:1 Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating	1995
Cabergoline in Parkinson's disease: long-term follow-up. Neurology, 1993, Volume: 43, Issue:12 Topics: Adult; Aged; Cabergoline; Dopamine Agents; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome	1993
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E	1995
Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Aged; Cabergoline; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Edema; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease	1995
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients. Journal of neural transmission. Supplementum, 1995, Volume: 45 Topics: Analysis of Variance; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome	1995
Cabergoline in Parkinson's disease complicated by motor fluctuations. Movement disorders : official journal of the Movement Disorder Society, 1996, Volume: 11, Issue:5 Topics: Aged; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Humans; Middle Aged; Parkinson Disease; Receptors, Dopamine D2	1996
Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biological & pharmaceutical bulletin, 1996, Volume: 19, Issue:11 Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine	1996
[Therapy of Parkinson disease. Continuous physiologic dopaminergic stimulation with carbergoline]. Der Nervenarzt, 1997, Volume: 68, Issue:3 Suppl Th Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Humans; Parkinson Disease	1997
[Cabergolin: new horizons in the therapy of Parkinson diseases]. Der Nervenarzt, 1998, Volume: 69, Issue:9 Suppl Ne Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Parkinson Disease; Restless Legs Syndrome	1998
Low dose cabergoline induced interstitial pneumonitis. The European respiratory journal, 1999, Volume: 14, Issue:4 Topics: Aged; Biopsy; Bronchoalveolar Lavage Fluid; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Lung Diseases, Interstitial; Male; Parkinson Disease; Radiography, Thoracic; Tomography, X-Ray Computed	1999
Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys. Progress in neuro-psychopharmacology & biological psychiatry, 2000, Volume: 24, Issue:4 Topics: Animals; Antiparkinson Agents; Binding Sites; Cabergoline; Disease Models, Animal; Ergolines; Female; In Situ Hybridization; Macaca fascicularis; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2	2000
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Disorders of Excessive Somnolence; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Thiazoles	2001
Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy. European neurology, 2001, Volume: 46 Suppl 1 Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Electrophysiology; Ergolines; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Parkinson Disease	2001
Cabergoline can increase penile erections and libido. Neurology, 2002, Mar-12, Volume: 58, Issue:5 Topics: Aged; Animals; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Libido; Male; Parkinson Disease; Penile Erection	2002
Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. The European respiratory journal, 1992, Volume: 5, Issue:2 Topics: Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Humans; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion	1992
Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids. Journal of immunoassay, 1992, Volume: 13, Issue:3 Topics: Aged; Cabergoline; Cross Reactions; Dopamine Agents; Ergolines; Evaluation Studies as Topic; Humans; Male; Parkinson Disease; Radioimmunoassay; Reference Standards; Sensitivity and Specificity	1992
Cardiopressor effects of short-term treatment with cabergoline in L-dopa stable responder parkinsonian patients: relevance of postprandial hypotension. Clinical neuropharmacology, 1991, Volume: 14, Issue:4 Topics: Aged; Blood Pressure; Cabergoline; Dopamine Agents; Ergolines; Female; Food; Heart Rate; Humans; Hypotension; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease; Time Factors	1991
Pleuropulmonary disease associated with dopamine agonist therapy. Annals of neurology, 1991, Volume: 30, Issue:4 Topics: Aged; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Lisuride; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Diseases; Radiography	1991
Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Annals of neurology, 1990, Volume: 28, Issue:4 Topics: Administration, Oral; Antiparkinson Agents; Cabergoline; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine	1990